View in EDS

Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer.

Saved in:
Bibliographic Details
Title: Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer.
Authors: Sammons S; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA. sarahl_sammons@dfci.harvard.edu., Yardley DA; Department of Medical Oncology, Sarah Cannon Research Institute, Nashville, TN, USA., Sharma P; Department of Internal Medicine, University of Kansas Medical Center, Westwood, KS, USA., Gadi VK; Division of Hematology and Oncology, University of Illinois Cancer Center, Chicago, IL, USA., Pegram M; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA., Pathak P; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Hu H; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Sopher G; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA., Fasching PA; Gynecology and Obstetrics Translational Medicine, University Hospital Erlangen Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
Source: Oncology and therapy [Oncol Ther] 2026 Mar; Vol. 14 (1), pp. 19-25. Date of Electronic Publication: 2025 Nov 14.
Publication Type: Editorial
Journal Info: Publisher: Adis Country of Publication: New Zealand NLM ID: 101677510 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2366-1089 (Electronic) Linking ISSN: 23661089 NLM ISO Abbreviation: Oncol Ther Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41239082
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Sammons+S%22">Sammons S</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Ave, Boston, MA, 02215, USA. sarahl_sammons@dfci.harvard.edu.<br /><searchLink fieldCode="AU" term="%22Yardley+DA%22">Yardley DA</searchLink>; Department of Medical Oncology, Sarah Cannon Research Institute, Nashville, TN, USA.<br /><searchLink fieldCode="AU" term="%22Sharma+P%22">Sharma P</searchLink>; Department of Internal Medicine, University of Kansas Medical Center, Westwood, KS, USA.<br /><searchLink fieldCode="AU" term="%22Gadi+VK%22">Gadi VK</searchLink>; Division of Hematology and Oncology, University of Illinois Cancer Center, Chicago, IL, USA.<br /><searchLink fieldCode="AU" term="%22Pegram+M%22">Pegram M</searchLink>; Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA, USA.<br /><searchLink fieldCode="AU" term="%22Pathak+P%22">Pathak P</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Hu+H%22">Hu H</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Sopher+G%22">Sopher G</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA.<br /><searchLink fieldCode="AU" term="%22Fasching+PA%22">Fasching PA</searchLink>; Gynecology and Obstetrics Translational Medicine, University Hospital Erlangen Comprehensive Cancer Center Erlangen-EMN, Erlangen, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101677510%22">Oncology and therapy</searchLink> [Oncol Ther] 2026 Mar; Vol. 14 (1), pp. 19-25. <i>Date of Electronic Publication: </i>2025 Nov 14.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Editorial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Adis%22">Adis </searchLink><i>Country of Publication: </i>New Zealand <i>NLM ID: </i>101677510 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2366-1089 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223661089%22">23661089 </searchLink><i>NLM ISO Abbreviation: </i>Oncol Ther <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41239082
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s40487-025-00394-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 19
    Titles:
      – TitleFull: Investigating Real-World Evidence and Reported Survival Outcomes of CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Sammons S
      – PersonEntity:
          Name:
            NameFull: Yardley DA
      – PersonEntity:
          Name:
            NameFull: Sharma P
      – PersonEntity:
          Name:
            NameFull: Gadi VK
      – PersonEntity:
          Name:
            NameFull: Pegram M
      – PersonEntity:
          Name:
            NameFull: Pathak P
      – PersonEntity:
          Name:
            NameFull: Hu H
      – PersonEntity:
          Name:
            NameFull: Sopher G
      – PersonEntity:
          Name:
            NameFull: Fasching PA
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2026 Mar
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 2366-1089
          Numbering:
            – Type: volume
              Value: 14
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Oncology and therapy
              Type: main
ResultId 1